Literature DB >> 22421155

Antiangiogenic agents: fueling cancer's hypoxic roots.

Sarah J Conley, Max S Wicha.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22421155      PMCID： PMC3350874          DOI： 10.4161/cc.19890

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  8 in total

1.  Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia.

Authors:  Sarah J Conley; Elizabeth Gheordunescu; Pramod Kakarala; Bryan Newman; Hasan Korkaya; Amber N Heath; Shawn G Clouthier; Max S Wicha
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

2.  Bevacizumab treatment for solid tumors: boon or bust?

Authors:  Daniel F Hayes
Journal:  JAMA       Date:  2011-02-02       Impact factor: 56.272

3.  First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study.

Authors:  Jonas Bergh; Igor M Bondarenko; Mikhail R Lichinitser; Annelie Liljegren; Richard Greil; Nataliya L Voytko; Anatoly N Makhson; Javier Cortes; Alain Lortholary; Joachim Bischoff; Arlene Chan; Suzette Delaloge; Xin Huang; Kenneth A Kern; Carla Giorgetti
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

Review 4.  Angiogenesis: an organizing principle for drug discovery?

Authors:  Judah Folkman
Journal:  Nat Rev Drug Discov       Date:  2007-04       Impact factor: 84.694

Review 5.  Antiangiogenic therapy and tumor progression.

Authors:  Mikhail V Blagosklonny
Journal:  Cancer Cell       Date:  2004-01       Impact factor: 31.743

Review 6.  Modes of resistance to anti-angiogenic therapy.

Authors:  Gabriele Bergers; Douglas Hanahan
Journal:  Nat Rev Cancer       Date:  2008-08       Impact factor: 60.716

7.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Authors:  John M L Ebos; Christina R Lee; William Cruz-Munoz; Georg A Bjarnason; James G Christensen; Robert S Kerbel
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743

8.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Authors:  Marta Pàez-Ribes; Elizabeth Allen; James Hudock; Takaaki Takeda; Hiroaki Okuyama; Francesc Viñals; Masahiro Inoue; Gabriele Bergers; Douglas Hanahan; Oriol Casanovas
Journal:  Cancer Cell       Date:  2009-03-03       Impact factor: 31.743
  8 in total
  4 in total

1.  Scheduling of anticancer drugs: timing may be everything.

Authors:  Astrid A M Van der Veldt; Adriaan A Lammertsma; Egbert F Smit
Journal:  Cell Cycle       Date:  2012-10-03       Impact factor: 4.534

2.  TFPI1 mediates resistance to doxorubicin in breast cancer cells by inducing a hypoxic-like response.

Authors:  Gerald F Davies; Arnie Berg; Spike D L Postnikoff; Heather L Wilson; Terra G Arnason; Anthony Kusalik; Troy A A Harkness
Journal:  PLoS One       Date:  2014-01-28       Impact factor: 3.240

3.  Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells.

Authors:  Alessia Brossa; Lola Buono; Benedetta Bussolati
Journal:  Oncotarget       Date:  2018-04-27

Review 4.  Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1.

Authors:  Terra Arnason; Troy Harkness
Journal:  Cancers (Basel)       Date:  2015-10-16       Impact factor: 6.639
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.